Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high ...

United Therapeutics Corporation ... to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Shares of United Therapeutics fell on pace for the largest ... Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales. Wall Street had expected revenue of $734.7 million ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.

United Therapeutics Corp. is a biotechnology company ... Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26 ...